Quantum BioPharma Hits New High

Quantum BioPharma (QNTM) is up 730% YTD following the successful launch of unbuzzd by its partner Celly Nutrition (now Unbuzzd Wellness Inc.), which is planning an IPO; unbuzzd is an alcohol metabolism accelerator targeting the growing $2.05 billion hangover remedy market and is supported by clinical trial data demonstrating reduced intoxication and hangover symptoms. Quantum BioPharma receives royalties from unbuzzd sales and retains rights for pharmaceutical applications, and is also advancing other assets, including REKVRY for alcohol misuse and Lucid-MS for neurodegenerative disorders, with Lucid-MS having completed a Phase I trial with positive safety results.

Analysis

Quantum BioPharma Ltd. (QNTM) has demonstrated extraordinary stock performance in 2025, with its share price increasing by 730% year-to-date, closing at $30.18 on June 19 and trading up a further 12% to $34 in premarket on June 20. This surge is largely attributed to developments surrounding its alcohol metabolism accelerator, unbuzzd, a beverage designed to reduce intoxication and hangover symptoms. Launched in August 2024 on Amazon by licensee Celly Nutrition (now Unbuzzd Wellness Inc.), unbuzzd targets the rapidly expanding global hangover remedy market, valued at $2.05 billion in 2022 and projected to reach $6.2 billion by 2030 with a 14.8% CAGR. Quantum BioPharma receives a 7% royalty on unbuzzd sales until $250 million in cumulative payments, then 3% in perpetuity, while retaining full rights for pharmaceutical applications. The efficacy of unbuzzd was supported by a February 2025 double-blind, placebo-controlled clinical trial, which showed significant acceleration in alcohol clearance, improved alertness, reduced impairment, and no adverse side effects. Further bolstering Quantum's prospects, its 20.11%-owned partner, Unbuzzd Wellness Inc., has engaged an investment bank for a potential IPO on a major U.S. stock exchange. Beyond unbuzzd, Quantum BioPharma is advancing REKVRY for alcohol misuse in emergency settings and Lucid-MS, a neuroprotective compound for Multiple Sclerosis, which completed a Phase I trial in February 2025 with no safety concerns and has an ongoing toxicology study expected to conclude this year. The initial alert for QNTM was at $5.74 on February 4, 2025, highlighting the substantial appreciation since.

Key Decisions for Investors

• Investors should evaluate the current valuation of QNTM following its significant 730% YTD appreciation against its multifaceted growth drivers, including unbuzzd royalties, the upcoming IPO of Unbuzzd Wellness Inc., and its pharmaceutical pipeline.
• Consider the de-risking milestones achieved, such as positive clinical trial data for unbuzzd and the successful Phase I trial for Lucid-MS, while acknowledging that REKVRY and pharmaceutical formulations of unbuzzd remain in earlier development stages.
• Monitor the progress and market reception of unbuzzd sales post-launch and the execution of Unbuzzd Wellness Inc.'s IPO, as these are key near-term catalysts for Quantum BioPharma's revenue and the value of its equity stake.